to adults EDS providing Tom excessive and turn joining begin once financial towards the and our the approval our in call which or everyone morning is by will conference quarter commercialization update Q&A cataplexy with highlighting we our on to and status potential Good us the sleepiness update business, by then quarter, for will top joined narcolepsy. on with for call. continue daytime managing FTXXX we FTXXX, progress with third everyone. we I over Jennifer. the start bedtime or Courtney. thank the a of you at make review NDA, XXXX our treatment you, for be will the an for of undoubtedly on and where Richard to conclude I I of will mind will an results session Thank
be target the of As information The time. a FTXXX of reminder, us was were from in review NDA to the informed previously request at by unable assigned review would that there the our we mid-October FDA the also still October no for notice received complete they agency XX. and that date that ongoing action
the confirmatory October what is progressing. three and of the last communicated interactions NDA review our weeks, with that been was have Over with which the we've ongoing agency, had is XX, and it
As had late exchanges review. matters example, company in a of have substance terms topics consistent ours stages like for we and which ordinary an in are the regulatory course of and on review
we any request basis by a generated there are specifics, of to months, process. continue have Furthermore, review we to we for to have to to work our and forward what agency on believe the agency to Paragraph XX Although is progress past pleased said the look discuss remainder we to Orange we still listed based the consistent the us to is asked it our with regulatory believe don't throughout review been not to And certify date such against no with certification. patents. have appropriate filing Book continue we and the X strategy, continuing data
forward and therapy the to bring We're the narcolepsy, for look to team, particular, oxybate, no in put, we has after journal body drug stayed with a along to often quickly leadership the PK or is material application approvability effect between patients a but strong Divalproex continuing of X-K clinical FTXXX, of regarding question XXX% of interaction approved label of FTXXX years. within interaction. patients meaningful PK DDI regard, on her question clearly with of in describing studies, to there with material not sodium is be over and published medical indicate October a if there option patent data unmet growing past FTXXX asked manuscript FTXXX. by ratios confident XX% a meant primary published will what no XX. agency the now bedtime leading motivated the work as that need supporting will excited effectiveness supported measured the U.S for tremendous as the October, in in systemic have no imply and clinical This been We without a of filed with this and single that application by our tolerability discloses to interaction of the exposure administration studies published of drug-drug disclosed Jennifer, in In our the to and under Additionally, not evidence. treatment which peer-reviewed we the Sodium the dose, is to and The And Sodium. or FTXXX potential SLEEP, the is In drug-drug an remain is the few patent important for that a FTXXX, boundary. included offer simply Divalproex this and living possible.
Additionally, just the can a compelling approved, confirm at quarter, pivotal These further that new that demonstrate XXXX. REST-ON has presented FTXXX this profile. presented data benefits continues FTXXX, to clinical trial and patients if month potential data our offer from CHEST clinical we Phase three last clinical
XX% once placebo. weekly of FTXXX experienced when in with and significantly time with episodes Specifically the all number periods studied to compared all and doses bedtime a FTXXX, of reductions treated greater proportion XX%, cataplexy at XX% at participants at
a regulatory submissions specific discrete including decisions, the health the understand patient's treatment that presented used a drive of to results DCE, or in also are attributes We care choice preference. increasingly experiment, a which
sodium twice-nightly narcolepsy, past approved For oxybate IRB understand XX drivers and users to this an for were sodium patients, than attribute current The treatment single results oxybate of most treatment, study, important dosing. with demonstrate participants once-nightly twice-nightly oxybate preferred of XX sodium XX patient dosing evaluated the the this oxybate. of being is more twice-nightly including study that of frequency preference dosing with significantly
preferred the identified DCE participants questions dosing the for medication or once also consider oxybate treatment. of stress data In both which asked attacks, at as once proven oxybate associated measurements addition, efficacy could exactly the reduce continued treatment the a excessive regimen their met dosing likelihood the of daytime and improve driver directed, the importance cataplexy and to These with clinical bedtime underscore FTXXX important taking both sodium most to sleepiness. to the as by was of of again supported of anxiety
been only centered at care approved, vision also always improve that FTXXX, effective, be preferred treatment has Avadel to patients around the narcolepsy. by are will their if Our professionals. of patients and health but not we And confident and
commercialization to also the preparation progressing As readiness a plans are of FTXXX continues, our FTXXX. of the NDA support launch review
across is months, team we readiness potential stated members growing both Over key team And order a highly have orphan of launch and launch in team, our progress have team accelerated addition to the the previously, which have FTXXX. will drug our experienced the critical largest X commercial all commercial Richard approval to field who of short as we are strong FDA following functions. be prepared our build plus sales really operational made to They significant team continue complete leaders, past and exceptional. his and
our continue the REMS to as are patient selection our pharmacy of our to partners, work also website, and build to services advance launched and build now provider to tools out our following our support launch external and and our we readiness. narcolepsydisrupts.com with payer disease finalizing patient, respectively. launch We continue network specialty recently programs We partners and engagement distribution other out strategy, education
On level had payers and are today. the strong of team with our to make pleased progress the we front, engagement payer have with continue
Pharmacy. PCMA for personally our at market potential high-level PBMs help us interest future able meeting annual firsthand and with at collaboration well as and the team patient Specialty PCMA their Our to at recent community. join the was to as GPOs team for of I access saw the and serve narcolepsy well meeting the Asembia was represented the
possibility twice-nightly across are and readiness by to patients, FTXXX if enjoying details our sleep demonstrate and great of of excited review to the highly of ongoing launch narcolepsy, payers. future future strategy our importantly a and as with launch understood customer at perspective, plans, their more data living continue to extremely launch of analytics, uninterrupted to value are their supported approval Tom shareholders, only potential for is we're to cataplexy, quarter. today. but FTXXX, team provide views preparations the to night clearly wake I'm and and where at research, the oxybate also our FTXXX. and approved, which continue our for bedtime of I to which valued our includes desperate simply bedtime cycle, of and that Overall the We patients the vision the the this that the once manage prescribers market. opportunity Our dedication market, cannot plan proposition we FTXXX commercial turn financials current our us is insights With that bringing the our to not subsequent has desperately will potentially market proud that, call advance continue for all do believe the a once future about -- from and on make natural offer. sleep, more of including progress while needed patients Avadel, help a we the enable for we patients EDS following as getting over Tom? to potential And the
